Original language | English (US) |
---|---|
Pages (from-to) | 685-686 |
Number of pages | 2 |
Journal | Molecular Therapy |
Volume | 22 |
Issue number | 4 |
DOIs | |
State | Published - Apr 2014 |
Bibliographical note
Funding Information:Nearly 40 years ago, the National Institutes of Health (NIH) Recombinant Advisory Committee (RAC) was chartered to address public and ethical concerns surrounding the development of recombinant DNA (rDNA) molecules for transfer across organisms. As the use of rDNA evolved toward first-in-human clinical trials, the RAC reoriented its mission toward review of human subject risks. With the reconfigured scope, the RAC had authority to review all NIH-funded rDNA studies, including approval of clinical trials separate from the US Food and Drug Administration (FDA).